Novo Nordisk stock: Novo files etavopivat in US, EU
Published on 11/19/2026 at 17:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory filing adds pipeline milestone
- Novo Nordisk submitted etavopivat applications in the United States and European Union for sickle cell disease.
- The HIBISCUS Phase 3 program reported a 27 percent reduction in vaso-occlusive crises versus placebo.
- Regulatory decisions on the applications are expected in 2027.
Novo Nordisk announced on November 12 that it had submitted etavopivat for regulatory approval in the United States and European Union. The filing adds a sickle cell disease program to the Danish drugmaker's near-term regulatory pipeline, while a decision is expected in 2027, according to the company's press release.
Etavopivat moves toward review
Novo submitted a New Drug Application to the US Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency. The company is seeking approval for adolescents and adults aged 12 years and older with sickle cell disease.
Etavopivat is an investigational once-daily oral therapy designed to activate the pyruvate kinase red blood cell isozyme. Novo said the FDA had previously granted Fast Track, Rare Pediatric Disease and Orphan Drug designations, while the European Commission had granted an Orphan Drug designation.
Phase 3 results support filing
The applications rely on the HIBISCUS development program. Novo said the Phase 3 results showed a 27 percent reduction in vaso-occlusive crises and a delay of about four months to the first crisis compared with placebo in topline results announced in April 2026.
The filing is a regulatory step rather than an approval. Novo expects the FDA and European Commission to act on the applications in 2027, leaving the commercial timing and eventual label dependent on those decisions.
Share price and investor focus
Novo Nordisk stock traded at 35.33 euros on Lang & Schwarz at 17:12 CET on Thursday, November 19, 2026.
Novo Nordisk at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Quoted price: 35.33 euros on Lang & Schwarz at 17:12 CET on November 19, 2026
- Pipeline program: Etavopivat for sickle cell disease
European market developments remain the broader backdrop for pharmaceutical shares; see Current market reports.
